Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93.17 CHF | +2.13% | +1.56% | +9.78% |
May. 31 | NOVARTIS AG : UBS reiterates its Buy rating | ZD |
May. 31 | European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's enterprise value to sales, at 4.12 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.78% | 210B | B- | ||
+40.73% | 739B | C+ | ||
+32.83% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+15.00% | 240B | B+ | ||
-5.52% | 206B | A+ | ||
+6.17% | 164B | C+ | ||
-0.45% | 162B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- Ratings Novartis AG